Business Context and Reporting Period
Company: Daxor Corporation (DXR)
Filing Type: Form 10-K Annual Report
Period Ended: December 31, 1996
Business Overview: Daxor operates in medical services and technology, primarily through its Idant Laboratory division (sperm and blood banking) and the development of the Blood Volume Analyzer (BVA-100). The company also maintains a significant portfolio of marketable securities.
Key Financial Metrics
| Metric | 1996 | 1995 |
|---|---|---|
| Total Revenues | $2,865,835 | $4,748,935 |
| Operating Revenues | $717,308 | $1,864,552 |
| Dividend Income | $2,132,173 | $2,209,962 |
| Net Income (Loss) | ($112,165) | $1,287,115 |
| Net Income Per Share | ($0.02) | $0.26 |
| Total Assets | $37,288,804 | $37,744,621 |
| Shareholders' Equity | $31,781,420 | $32,052,831 |
| Working Capital | $31,006,579 | $31,598,345 |
| Short-Term Debt | $1,636,067 | $1,536,609 |
| Cash and Equivalents | $123,115 | $1,987 |
Note: The company's financial performance is heavily supported by investment income (dividends and gains) rather than core operating revenues.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased by approximately 40% from 1995 to 1996. This was driven by a 61% drop in operating revenues ($1.86M to $0.72M) and a significant reduction in gains from the sale of investments ($674k to $16k).
- Profitability Reversal: The company shifted from a net income of $1.29 million in 1995 to a net loss of $112,165 in 1996.
- Operational Disruption: The decline in operating revenue is directly attributed to the revocation of licenses by the New York State Department of Health (NYSDOH) on August 21, 1995, which forced a partial closure of the Idant blood and sperm banks until May 1996.
- Liquidity Improvement: Cash and cash equivalents increased significantly from $1,987 to $123,115, despite the net loss, due to cash flow adjustments and investment activities.
Outlook, Risks, and Management Commentary
Management Commentary and Outlook
- Regulatory Victory: On May 16, 1996, the NY Appellate Court unanimously ordered the reopening of Daxor's facilities, reversing the NYSDOH's closure order. Management expects this to restore revenue streams.
- BVA-100 Launch: The Blood Volume Analyzer (BVA-100) has received FDA approval for its required isotope (Albumin I-131) after an eight-year delay. Manufacturing agreements with Oxford Instruments are in place. The device is currently under 510(k) review by the FDA.
- Expansion Plans: The company plans to develop a nationwide network of cryo-centers for blood and sperm banking, potentially requiring additional financing.
Risks and Contingencies
- Legal Proceedings: Daxor is engaged in a $100 million RICO/Anti-trust lawsuit against the New York Blood Center and NYSDOH officials, alleging collusion to destroy the company's frozen blood banking program. The outcome is uncertain but could result in significant recovery or further costs.
- Regulatory Hostility: The company faces ongoing opposition from established blood banking monopolies and regulatory bodies, which has historically impeded market entry and operations.
- Market Acceptance: Success of the BVA-100 depends on demonstrating cost-effectiveness and overcoming the entrenched practices of current blood volume estimation methods.
Investor Verification Checklist
- License Status: Confirm the current operational status of the Idant blood and sperm banks following the May 1996 court order and any subsequent regulatory actions.
- FDA Approval: Verify the status of the 510(k) application for the BVA-100 and the injection kit, as commercialization depends on final approval.
- Legal Litigation: Monitor the progress of the $100 million RICO/Anti-trust suit and the potential for damages recovery or further legal expenses.
- Investment Portfolio: Assess the sustainability of the company's reliance on dividend income and unrealized gains from its securities portfolio to offset operating losses.
- Debt Covenants: Review the terms of the short-term loans ($1.6M) secured by marketable securities to ensure compliance with margin requirements.